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Abstract 
Researchers often attempt to categorize tumors into more homogeneous subtypes to better predict 
prognosis or understand pathogenic mechanisms. In clinical research, typically the focus is on 
prognosis: the tumor subtypes are intended to be associated with specific responses to treatment 
and/or different clinical outcomes. In aetiological research, the focus is on identifying distinct 
pathogenic mechanisms, which may involve different risk factors. We used directed acyclic graphs 
to present a framework for considering potential biases arising in aetiological research of tumor 
subtypes, when there is incomplete correspondence between the identified subtypes and the 
underlying pathogenic mechanisms.  We identified two main scenarios: (i) weak effect, when the 
tumor subtypes are identified through combinations of characteristics and some of these 
characteristics are affected by factors that are unrelated with the underlying pathogenic 
mechanisms; and (ii) lack of causality, when the set of characteristics corresponds with a 
mechanism that is actually not a cause of the tumor of interest. Examples of the magnitude of bias 
that can be introduced in these situations are provided. Although categorization of tumors into 
homogenous subtypes may have important implications for aetiological research and identification 
of risk factors, the characteristics used to classify tumors into subtypes should be as close as 
possible to the actual pathogenic mechanisms to avoid interpretative biases. Whenever our 
knowledge of these mechanisms is limited, research into risk factors for tumor subtypes should first 
aim to causally link the characteristics to the pathogenic mechanisms.  
 
Keywords: cancer subtypes, molecular characteristics, bias, disease classification, aetiological 
research 
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Introduction 
Clinical and aetiological research often aims to categorize disease entities into more homogeneous 
subtypes to better predict prognosis, or to improve the understanding of pathogenic mechanisms. 
Typically, a disease is classified into subtypes that share specific characteristics. In particular, any 
characteristic associated with prognosis and/or response to treatment may identify subtypes that 
differ regarding their clinical outcome; however, the same characteristics may not correspond to 
specific aetiologic mechanisms, and vice versa.  
Research into the identification of disease subtypes has recently increased due to advances in high-
throughput techniques to explore molecular patterns, the availability of large biological databases, 
and the implementation of collaborative initiatives to obtain and analyze large numbers of tissue 
samples in a standardized fashion. This increased research activity is tightly linked with the concept 
of precision medicine which involves the identification of disease subtypes to better target the 
treatment, estimate prognosis and/or manage clinical follow-up. This concept is having a particular 
impact on clinical oncology and cancer research [1], but is being adopted also in non-malignant 
diseases, including, for example, asthma [2], cardiovascular disease [3] and diabetes [4].  
A related development is to use disease subtypes in aetiological studies.  Through unsupervised 
cluster analysis, for example, breast cancer researchers have identified subtypes of breast cancer, 
based on the expression of ESR1 (estrogen receptor), PGR (progesterone receptor), and ERBB2 
(HER2) [5]. While this classification is usually adopted for prognosis and to inform therapeutic 
choices [6], it has been recently proposed to use it for etiological purposes. Epidemiological studies 
have shown that triple negative breast cancer may have specific risk factors [7].  
Traditionally, tumor classification has been primarily based on the anatomical site of origin of the 
tumor [8]. Then, within each tumor site, stratification is typically carried out on the basis of the cell 
type of origin and, sometimes, other specific characteristics. It is now becoming increasingly 
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possible to further subdivide the tumors on the basis of their molecular features [9]. Thus the 
process of identification of tumor subtypes currently goes from the identification of an organ-
specific tumor (e.g. “breast cancer”), to the classification of that tumor into specific subtypes (e.g. 
“triple-negative breast cancer” or even finer subtypes [10, 11]).  
It is debatable whether such tumor subtypes represent subtypes of a single disease, or should be 
treated as different diseases. We will approach this issue pragmatically assuming that an organ-
specific tumor type has been identified, and the issue is whether and how to divide this into 
subtypes. This approach mimics the current clinical approach to tumor heterogeneity: the 
characterization of tumor subtypes – often based on molecular analyses of the tumor tissue - 
logically follows the diagnosis of the tumor as an organ-specific entity. For example, a patient is 
first diagnosed with a breast cancer and, then, after having the results of immunohistochemistry 
assays on the tumor tissue, that tumor is further subclassified on the basis of the receptor status.   
We support the need to reach a clearer definition of tumors in terms of pathogenic mechanisms. 
However, in this paper we argue that aetiological research into tumor subtypes may, under some 
circumstances, be problematic. A better understanding of these limitations is required for 
appropriate planning and interpretation of aetiological studies based on tumor subtypes. In this 
paper, we first present a conceptual framework for considering the correspondence between 
pathogenic mechanisms and the identification of the disease subtypes. We then assess two scenarios 
in which there is not a direct correspondence between the characteristics and distinct pathogenic 
mechanisms: (i) weak effect, when the tumor subtypes are identified through combinations of 
characteristics and some of these characteristics are affected by factors that are unrelated with the 
underlying pathogenic mechanisms; (ii) lack of causality, when the set of characteristics 
corresponds with a mechanism that is actually not a cause of the tumor of interest. Finally we 
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provide some suggestions on how to conduct research to establish the links between the 
characteristics and the pathogenic mechanisms.  
 
Tumor subtypes and pathogenic mechanisms  
In the context of aetiological research, tumor subtypes have aetiological value if they identify 
distinct pathogenic mechanisms. In Fig. 1 we use directed acyclic graph (DAG) to depict the 
supposed causal relationships between the diagnosis of a tumor, the identification of the tumor 
subtypes, and the associated pathogenic mechanisms: E denotes an exposure, A denotes a 
pathogenic mechanism causing an organ-specific tumor T and C is a characteristic that is used alone 
or in combination with other characteristics to define the tumor subtypes S once the tumor T has 
been diagnosed.  Both of the pathogenic mechanisms (A1, A2) lead to the development the tumor T. 
However tumors caused by the two mechanisms will show different characteristics (C1 and C2), 
which are then used to define the disease subtypes S. It is also possible that the characteristics used 
to define the tumor subtypes contribute to the initial diagnosis of the tumor, in which case there 
would be arrows from C1 and C2 to T. However, in the current example, we assume that the 
characteristics that are used to define the subtypes are not used to reach the first diagnosis, but are 
evaluated after the diagnosis of the tumor.    
For simplicity, in Fig. 1 and throughout the article we assume that all variables are binary.  It is thus 
assumed that a tumor can have two subtypes: the first is due to A1 (and identified through C1), the 
second is due to A2 (and identified through C2). If it is biologically possible that A1 and A2 coexist 
(as, for example, in the case of intratumor heterogeneity), then the two subtypes can also coexist. A 
simple example of the scenario described in Fig. 1 is the sub-classification of tumors on the basis of 
the cell type of origin. For example germ-line testicular cancer can be divided into seminomas and 
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nonseminomas: these are biological and, potentially, clinical different subtypes, and it is not 
uncommon that a seminoma and a nonseminoma coexist in the same patient.  
 In the model proposed in Fig. 1, the subtypes directly correspond to pathogenic mechanisms. The 
exposures may act specifically on a pathogenic mechanism (E1 or E3) or may be shared by the 
different pathogenic mechanisms (E2). It should be noted that C1 and C2 may be a set of 
characteristics (rather than single characteristics), but should still be specific for a single pathogenic 
mechanism.  
 
Problems of causal interpretation 
It is possible that the assumption of direct correspondence between the characteristics used to define 
the subtypes and the pathogenic mechanism is not valid. This may affect the interpretability of 
aetiological studies of tumor subtypes. We discuss two scenarios, which are shown, respectively, in 
Fig. 2 (hereafter labeled as “weak effect”) and Fig. 3 (hereafter labeled as “lack of causality”)   
 
Scenario 1: Weak effect 
In the scenario depicted in Fig. 2a, the set of characteristics C2 is caused by both pathogenic 
mechanisms A1 and A2, thus a subtype is defined by the presence of C1 and C2, while the other 
subtype has only C2 features. This scenario may apply whenever the tumor subtypes are defined by 
combinations of characteristics (the definition of breast cancer subtypes, for example, requires the 
combination of ESR1 and PGR expression with ERBB2 expression). The situation depicted in Fig. 
2a would lead to correct causal interpretations. However there may be problems of causal 
interpretation if, as shown in Fig. 2b, some of the characteristics used to define the tumor subtypes 
are affected by factors that are unrelated with the pathogenic mechanisms. In Fig. 2b, the exposure 
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E4 affects the characteristic C1 without acting on the pathogenic mechanism A1. Since C1 is 
explained also by E4, the pathogenic mechanism A1 is not a necessary and sufficient cause of C1 and 
thus its effect on C1 is weakened (hence the label weak effect).  
The scenario described in Fig. 2b, in which the characteristic C1 is caused by both the pathogenic 
mechanism A1 and the exposure E4, may imply that: (i) some individuals have the set of 
characteristics C1 for mechanisms that are unrelated with the pathogenic mechanism A1; or that (ii) 
the pathogenic mechanism A1 does not always produce the associated characteristics C1. These two 
mechanisms are not mutually exclusive. Their consequence is that individuals who experience the 
pathogenic mechanism A2 can have both C1 and C2 and be spuriously attributed to the pathogenic 
mechanism A1, and, vice versa, individuals who experienced the pathogenic mechanism A1 can 
have only C2 and be spuriously attributed to the pathogenic mechanism A2. These effects can be 
seen in Fig. 2b when considering the effect of conditioning on C1 on its two causes A1 and E4. If all 
variables are binary (0=absent, 1=present): (i) C1=1 does not imply necessarily that A1=1, as 
presence of C1 could be due also to E4=1, and (ii) C1=0 does not imply necessarily that A1=0 if 
there is an interaction between E4 and A1 that produces C1=0 when, for example, A1=1 and E4=1. It 
follows that presence of C1 may occur in absence of A1 and absence of C1 may occur in presence of 
A1.   
It should be noted that the problems described here relate to the underlying biological mechanisms 
leading to the tumor subtypes, and are therefore different from problems of measurement error and 
misclassification of the characteristics Cs. They occur even if the characteristics Cs are perfectly 
measured.  
 
Scenario 2: Lack of causality 
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A different problem may occur if one of the supposed pathogenic mechanisms leading to the 
characteristics used to define the subtypes is not a cause of the tumor. The DAG shown in Fig. 3 
depicts such a scenario in which A2 is not a cause of the disease, and thus there is not an arrow from 
A2 to T. The corresponding characteristic C2 could still have a prognostic role, but it would not be a 
marker of a pathogenic mechanism. For example, methylation in the promoter of the O6-
methylguanine methyltransferase (MGMT) gene in glioblastoma affects response to treatment with 
telozolemide  (and it is thus relevant clinically), but this molecular alteration might not be a driver 
in the pathogenesis of this cancer type. Under this scenario, any risk factor for A2 (and thus C2) 
would be associated with the both disease subtypes defined on the basis of C2 (presence or absence 
of C2) even if this risk factor does not have any aetiological role for the tumor of interest.  
 
Numerical examples 
In Table 1, we use the scenario of Fig. 2b and consider a tumor caused by two possible pathogenic 
mechanisms: A1 which always causes the characteristics C1 and C2, and A2 which always causes 
only the characteristic C2. We also assume that an exposure E3 doubles the risk of A2. We assume 
that the population risk of A1 is 1 per 1000 and that the population risk of A2 is 1 per 1000 when 
E3=0 and 2 per 1000 when E3=1. We assume complete case ascertainment and diagnosis, 
irrespective of the mechanism involved, and that all variables are measures with no error. We also 
assume a 10% risk of developing the characteristic C1 for reasons that are unrelated with the disease 
of interest (compared to 100% of subjects who are affected by A1). Finally, we assume that the two 
mechanisms A1 and A2 can coexist, even if in this particular example, this assumption has negligible 
effects because the risks of A1 and A2 are low.  
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Using these assumptions, Table 1 gives an example of the weak effect scenario caused when C1 can 
occur also in individuals without the disease of interest. Although the exposure E3 affects only the 
pathogenic mechanism A2 (which corresponds to tumor subtype 2 – S2 –), analyses based on tumor 
subtypes would suggest that E3 also affects S1 (which corresponds to the unaffected pathogenic 
mechanism A1).  
 
In Table 2, we also assume that only 50% of the subjects having the pathogenic mechanism A1 will 
in fact have the characteristic C1. This, in combination with the occurrence of C1 in subjects without 
the disease, further contributes to the interpretative problems due the weak effect scenario: the risk 
ratio for S2 (corresponding to the pathogenic mechanism A2) underestimates the effect of E3 on A2 
(RR of 1.67 vs. a true RR of 2.00), while the risk ratio for S1 further overestimates the effect of E3 
on A1 (RR of 1.15 vs. a true RR of 1.00).   
 
Finally, Table 3 gives an example of the lack of causality scenario. There are only two possible 
subtypes (based on the presence or absence of C2) as A2 is not causal for the disease, and thus the 
pathogenic mechanism A1 (and C1=1) is a necessary cause. In Table 3 we assume that the 
population risk of A1 is 1/1000 irrespectively of the level of the exposure E3, while E3 doubles the 
risk (from 10% to 20%) of another mechanism A2 unrelated with the tumor of interest. We also 
assume that A1 always causes C1, A2 always causes C2, no case is left undiagnosed and all variables 
are measured correctly. Since the characteristic C2 is unrelated with any pathogenic mechanism for 
the disease, when the analyses are stratified on C2, the overall group of cases is divided into two 
groups which are in fact homogeneous in terms of aetiology. An exposure E3 affecting C2 would 
thus increase the number of patients labeled as having a “C2 tumor subtype”, and thus decrease the 
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number of patients with a “non-C2 like tumor”. It follows that E3 would be incorrectly considered to 
be a risk factor for the C2 tumor subtype and a protective factor for the non-C2 tumor subtype.. 
 
Discussion  
Categorization of tumors into homogenous subtypes can help to identify specific pathogenic 
mechanisms and thereby specific risk factors [12]. There has recently been increasing interest in the 
definition and detection of tumor subtypes. This has been given impetus by recent advances in 
various omics technologies and the resulting increase in the amount of clinically relevant 
information that is available. Intertumor heterogeneity [13] and molecular pathological 
epidemiology [14, 15] are fast developing and influential concepts in cancer research. A similar 
increasing attention to the identification of disease subtypes has been occurring for non-cancer 
diseases. For example, already in 1995, an influential paper identified three asthma phenotypes 
based on combinations of age at onset and persistency of wheezing [16]. This classification, as well 
as subsequent developments including additional clinical characteristics and inflammation markers 
[17] have been used in a large number of aetiological studies on the assumption that “considering 
these more homogeneous phenotypes in future studies may lead to a better identification of risk 
factors for asthma” [18].  
As discussed in this paper, the markers used to sub-classify tumors into tumor subtypes should be 
as close as possible to the actual pathogenic mechanisms. Although this correspondence is crucial 
to avoid interpretative biases, our knowledge of the pathogenic mechanisms is often too limited to 
assess whether this important criterion has been achieved. The classification of breast cancer 
subtypes, for example, based on the expression of the estrogen and progesterone receptors and 
ERBB2, has been suggested through a cluster analysis; even if its clinical value has been proven, 
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distinct pathogenic mechanisms for the different subtypes have not yet been demonstrated. In fact, 
a recent commentary on breast cancer suggests the existence of only two aetiological components 
(which would correlate with the expression of the ESR1); it argues that, even if the model may 
seem too simplistic clinically, it is not too simple for aetiological purposes, considering that many 
molecular alterations may be more linked with tumor progression than with its development [19].  
We suggest that aetiological research into tumor subtypes should first aim to connect the pathogenic 
mechanisms to the relevant characteristics, and then use these characteristics to assess whether the 
disease subtypes have different risk factors. Biological knowledge is a key factor. For example, 
when the subtypes are identified on the basis of the cell type of origin, it can be reasonably 
assumed, solely on a biological basis, that different cell types are involved in different pathogenic 
mechanisms. They may share risk factors, as, for example, small cell lung carcinoma and lung 
adenocarcinoma are both affected by smoking [20], but the pathogenic mechanisms remain 
different as they involve different cell types.  
Often, however, biological knowledge is not sufficient to link a characteristic to a pathogenic 
mechanism and research should be conducted with the primary aim of establishing such a link. 
There are several options. First, characteristics that are evident at an early tumor stage are more 
likely to be causally linked to its aetiology than late characteristics. Tumor cells evolve during the 
tumor lifespan, acquiring new and complex molecular features. If we are however interested in 
primary prevention and early development of the tumor, molecular characteristics acquired at a later 
stage are less relevant and may easily be affected by mechanisms that are not related with the risk 
factors of interest. Thus, studies that have access to pre-diagnostic tissues are highly informative to 
define tumor subtypes for aetiological studies [21]. Once the subtypes are defined, they can be 
identified also on the diagnostic tissue, but an initial step involving pre-diagnostic tissue and early 
molecular characteristics would greatly enhance the potential to validly interpret subsequent studies.  
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Second, the risk of interpretative bias may be reduced by defining tumor subtypes on the basis of 
subtype-specific sets of characteristics (i.e. each subtype has different identifying characteristics) 
instead of combinations of characteristics partially shared by different pathogenic mechanisms. This 
should be taken into account, for example, when the tumor subtypes are defined on the basis of an 
unsupervised cluster analysis, and then a set of markers is chosen to characterize each specific 
cluster. For aetiological research, it is perhaps safer if the characterizing sets of markers do not 
overlap among clusters. Third, in some instances it is possible to directly test whether a 
characteristic is causally involved in tumor development. For example, to understand whether gene-
specific methylation is causally involved in tumor development, it is possible to study the 
association between germ-line variants in the DNA methylation machinery genes and cancer 
incidence [22]. If an association is found, methylation markers are more likely to be causally 
involved instead of being just epiphenomena. This approach, which is based on the concept of 
Mendelian randomization, can be carried out almost systematically, at least for characteristics that 
are known to be affected by germ-line variants.   
In conclusion, categorization of tumors into homogenous subtypes may have important implications 
for aetiological research and identification of risk factors. However, it is essential that the 
characteristics used to classify tumors into subtypes should be as close as possible to the actual 
pathogenic mechanisms to avoid interpretative biases. Whenever our knowledge of these 
mechanisms is limited, research into risk factors for tumor subtypes should first aim to causally link 
the characteristics to the pathogenic mechanisms. 
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Fig. 1. Simplified diagram showing the relationship between exposures (E), pathogenic mechanisms 
(A), the organ-specific tumor (T), characteristics (C) and subtypes (S). 
 
Fig. 2. Diagram depicting a situation in which the set of characteristics (C) used to define the 
disease subtypes (S) are not always specifically linked to a given pathogenic mechanism (A). 2a) E 
denotes an exposure potentially causing at least one of pathogenic mechanisms and T denotes the 
organ-specific tumor diagnosis. 2b) A further exposure (E4) causes one of the characteristics used to 
define the subtypes but it is not a cause of any of the pathogenic mechanisms of interest. 
 
Fig. 3. Diagram depicting a situation of lack of causality. The set of characteristics (C) used to 
define the disease subtypes (S) are linked with pathogenic mechanisms (A) which are (A1) or are 
not (A2) causes of the disease T of interest. E denotes an exposure potentially causing at least one 
of pathogenic mechanisms.   
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Table 1. Example of a weak effect scenario. Probabilities of different combinations of presence of 
an exposure E3, pathogenic mechanisms A1 and A2, characteristics C1 and C2 and subtypes S1 (C1=1 
and C2=1) and S2 (C1=0 and C2=1), when the characteristic C1 may occur also among subjects 
without the disease. Relationships among the variables are described in Fig. 2b. 
 
Exposure Pathogenic mechanisma Subtypeb 
 A1 A2 S1  
(C1=1, C2=1) 
S2 
 (C1=0, C2=1) 
E3=1 0.001 0.002 0.0012 0.0018 
E3=0 0.001 0.001 0.0011 0.0009 
Risk ratioc 1.00 2.00 1.09 2.00 
a These probabilities are assumed by design (see text for details) 
b These probabilities are obtained on the basis of A1 and A2, assuming that A1 always generates C1 
and A2 always generates C2 and a 10% risk of developing the characteristic C1 for reasons that are 
unrelated with the disease of interest (see text) 
c Risk ratios are calculated by dividing the disease probabilities in E3=1 for disease probabilities in 
E3=0. Other approaches are possible, which, however, would give the same results as we assumed a 
rare disease 
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Table 2. Example of a weak effect scenario. Probabilities of different combinations of presence of 
an exposure E3, pathogenic mechanisms A1 and A2, characteristics C1 and C2 and subtypes S1 (C1=1 
and C2=1) and S2 (C1=1 and C2=1), when the characteristic C1 may occur also among subjects 
without the disease and the pathogenic mechanism A1 does not always produce C1. Relationships 
among the variables are described in Fig. 2b. 
Exposure Pathogenic mechanisma Subtypeb 
 A1 A2 S1  
(C1=1, C2=1) 
S2 
 (C1=0, C2=1) 
E3=1 0.001 0.002 0.00075 0.00225 
E3=0 0.001 0.001 0.00065 0.00135 
Risk ratioc 1.00 2.00 1.15 1.67 
a These probabilities are assumed by design (see text for details) 
b These probabilities are obtained on the basis of A1 and A2 and assuming that A1 always causes C2 
and causes C1 in 50% of the affected subjects, while A2 always causes C2. We also assume a 10% 
probability of C1 in subjects not having A1 (see text) 
c Risk ratios are calculated by dividing the disease probabilities in E3=1 for disease probabilities in 
E3=0. Other approaches are possible, which, however, would give the same results as we assumed a 
rare disease 
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Table 3. Example of a lack of causality scenario. Probabilities of different combinations of 
presence of an exposure E3, pathogenic mechanisms A1 and A2 (the latter is not a cause of the 
disease of interest), characteristics C1 and C2, and C2-subtype (C1=1 and C2=1) and non C2-subtype  
(C1=1 and C2=0).  The relationships among the variables are described in Fig. 3 
Exposure Pathogenic mechanisma Subtypeb 
 A1  
(causing 
the disease) 
A2  
(not causing the 
disease) 
non C2-subtype C2-subtype 
E3=1 0.001 0.2 0.0008 0.0002 
E3=0 0.001 0.1 0.0009 0.0001 
Risk ratioc 1.00 2.00 0.89 2.00 
a These probabilities are assumed by design (see text for details) 
b These probabilities are obtained on the basis of A1 and A2 and assuming that only A1 causes the 
disease of interest 
c Risk ratios are calculated by dividing the disease probabilities in E3=1 for disease probabilities in 
E3=0. Other approaches are possible, which, however, would give the same results as we assumed a 
rare disease 
 
